Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Anders Muusfeldt Birck, Liv Nordin Christensen, Mikkel H. Pedersen, Jens Olsen, Kelly D. Johnson, Goran Bencina, Thomas Holtkøtter Clausen & Carsten Schade Larsen. (2021) Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark. Expert Review of Vaccines 20:10, pages 1327-1337.
Read now
Read now
J. P. Sevilla, Andrew Stawasz, Daria Burnes, Anubhav Agarwal, Basak Hacibedel, Kerem Helvacioglu, Reiko Sato & David E. Bloom. (2020) Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey. Human Vaccines & Immunotherapeutics 16:8, pages 1923-1936.
Read now
Read now
Yiling Jiang, Xiaoqin Yang, Kazuko Taniguchi, Tanaz Petigara & Machiko Abe. (2018) A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. Journal of Medical Economics 21:7, pages 687-697.
Read now
Read now
Barbara Rita Porchia, Paolo Bonanni, Angela Bechini, Gugliemo Bonaccorsi & Sara Boccalini. (2017) Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Review of Vaccines 16:2, pages 93-107.
Read now
Read now
Yiling Jiang, Aline Gauthier, Sam Keeping & Stuart Carroll. (2014) A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 901-911.
Read now
Read now
Yiling Jiang, Aline Gauthier, Sam Keeping & Stuart Carroll. (2014) Cost–effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 913-927.
Read now
Read now
Articles from other publishers (13)
Hanyue Ding, Junjie Huang, Chun Ho Ngai, Qingjie Sun, Kin-On Kwok, Harry HX Wang, Marc Chong & Martin CS Wong. (2022) The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study. Vaccine 40:9, pages 1282-1288.
Crossref
Crossref
Xiaodong Sun, Yuekun Tang, Xiaoying Ma, Xiang Guo, Zhuoying Huang, Jia Ren, Jing Qiu, Hongli Jiang & Yihan Lu. (2021) Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China. Frontiers in Public Health 9.
Crossref
Crossref
Tinevimbo Shiri, Kamran Khan, Katherine Keaney, Geetanjali Mukherjee, Noel D. McCarthy & Stavros Petrou. (2019) Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions. Value in Health 22:11, pages 1329-1344.
Crossref
Crossref
Marina Treskova, Stefan M. Scholz & Alexander Kuhlmann. (2019) Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. PharmacoEconomics 37:9, pages 1093-1127.
Crossref
Crossref
J.P. Sevilla, Andrew Stawasz, Daria Burnes, Peter Bo Poulsen, Reiko Sato & David E. Bloom. (2019) Indirect costs of adult pneumococcal disease and productivity-based rate of return to PCV13 vaccination for older adults and elderly diabetics in Denmark. The Journal of the Economics of Ageing 14, pages 100203.
Crossref
Crossref
Ulrike Kuchenbecker, Daniela Chase, Anika Reichert, Julia Schiffner-Rohe & Mark Atwood. (2018) Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. PLOS ONE 13:5, pages e0197905.
Crossref
Crossref
Alvaro Mitsunori Nishikawa, Ana Marli Christovam Sartori, Giulia Marcelino Mainardi, Angela Carvalho Freitas, Alexander Itria, Hillegonda Maria Dutilh Novaes & Patrícia Coelho de Soárez. (2018) Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older. Vaccine 36:19, pages 2510-2522.
Crossref
Crossref
Elizabeth T. Cafiero-Fonseca, Andrew Stawasz, Sydney T. Johnson, Reiko Sato & David E. Bloom. (2017) The full benefits of adult pneumococcal vaccination: A systematic review. PLOS ONE 12:10, pages e0186903.
Crossref
Crossref
Jung Yeon Heo, Yu Bin Seo, Won Suk Choi, Jacob Lee, Ji Yun Noh, Hye Won Jeong, Woo Joo Kim, Min Ja Kim, Hee Young Lee & Joon Young Song. (2017) Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLOS ONE 12:5, pages e0177342.
Crossref
Crossref
Alexander Kuhlmann & J.-Matthias Graf von der Schulenburg. (2016) Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. The European Journal of Health Economics 18:3, pages 273-292.
Crossref
Crossref
Daijun Zhao, Ruoyan Gai Tobe, Min Cui, Jinchun He & Bin Wu. (2016) Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine 34:50, pages 6158-6165.
Crossref
Crossref
Livio Garattini, Anna Padula & Milene Rangel Da Costa. (2015) Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?. PharmacoEconomics 34:3, pages 221-224.
Crossref
Crossref
Jose Miguel Rodríguez González-Moro, Rosario Menéndez, Magda Campins, Nadia Lwoff, Itziar Oyagüez, María Echave, Javier Rejas & Fernando Antoñanzas. (2015) Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Clinical Drug Investigation 36:1, pages 41-53.
Crossref
Crossref